



# MaxCyte Announces Research Agreement with Kite

November 12, 2018 12:00 PM EST

Released : November 12, 2018 07:00

RNS Number : 9788G

MaxCyte, Inc.

12 November 2018

## **MaxCyte, Inc.**

("MaxCyte" or the "Company")

### **MaxCyte Announces Research Agreement with Kite, a Gilead Company**

**Gaithersburg, Maryland - 12 November 2018:** MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announced today that it has entered into a research agreement with Kite, a Gilead Company. Under the terms of the agreement, Kite will use MaxCyte's Flow Electroporation® Technology platform to enable non-viral cell engineering.

"We're excited to provide Kite the ability to leverage our versatile cell engineering platform to enable gene-editing technologies for research and development of important new therapeutics," said Doug Doerfler, President & CEO of MaxCyte, Inc. "This agreement further underlines MaxCyte's position as a leader in non-viral cell engineering for cell therapies."

#### **About MaxCyte**

MaxCyte is a global cell-based medicines and life sciences company applying its

patented cell engineering technology platform to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology platform to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer.

MaxCyte has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit [www.maxcyte.com](http://www.maxcyte.com).

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

For further information, please contact:

**MaxCyte Inc.**

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

***Nominated Adviser and Broker***

**Panmure Gordon**

+44 (0)20 7886 2500

Emma Earl

Freddy Crossley

**Corporate Broking**

James Stearns

***Financial PR Adviser***

**Consilium Strategic Communications**

+44 (0)203 709 5700

Mary-Jane Elliott

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

Chris Welsh

Sukaina Virji

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.rns.com](http://www.rns.com).

END

AGREADFFFEDPFAF